Valoración Clínica y Calidad de Vida relacionada con la Salud del Paciente con Insomnio

objective: clinical assessment and quality of life of the insomniac patient. design: cross-sectional study. setting: primary health care. toledo (spain). participants: patients diagnosed with insomnia before january 2009. measurements: medical history review: record of diagnostic and therapeutic activities. telephone interview: sleep history and eq-5d questionnaire results: n = 94. average age 60.3 ± 14.3 years, 79.8% are women. 73.4% (95%ci 62.0-80.0%) had less than 90% sleep efficiency and 69.1% said they sleep badly. impact: 76.8% get up feeling tired; in 70.6% insomnia interferes with their activities, in 63.2% it causes distractions and in 39.7% daytime sleepiness. 58.1% have conciliation insomnia, 25.8% have maintenance insomnia, and 8.6% early awakening. 27.8% of patients received advice on sleep hygiene. the most commonly prescribed drugs were lorazepam (47.2%), lormetazepam (23.6%) and zolpidem (19.1%). median duration of treatment was 32 weeks (ri 58). currently 24.7% are not taking any treatment, 21.7% of whom said they sleep well. 17.2% of those who were treated and 26.1% of those who were not considered they were in good or very good health. older patients (r= -0.33; p = 0.001), those who said they sleep badly (55.8 vs 53.2; t = 0, 52; p > 0.05), those with early awakening (f = 3.51; p = 0.01) and those on pharmacotherapy (51.5 vs 61.5; t = 1.93 p = 0.06) had the worst scores in the eq5d. conclusions: most patients with insomnia continue to sleep badly and have poor sleep efficiency, even with pharmacological treatment. the main impact is tiredness, which interferes with their normal activities. insomnia has a negative effect on the quality of life.